TY - JOUR
T1 - Antibiotics for the Treatment of Febrile Children with Neutropenia and Cancer
AU - Rubin, Marc
AU - Pizzo, Philip A.
AU - Shenep, Jerry L.
AU - Hughes, Walter T.
PY - 1989/4/6
Y1 - 1989/4/6
N2 - To the Editor: The question of whether vancomycin should be included routinely in the initial empirical antibiotic regimen for febrile, neutropenic patients with cancer is important and relevant. Gram-positive organisms are increasing in incidence, and many are resistant to or poorly covered by most regimens that do not contain vancomycin. Thus, some authorities have recommended that vancomycin be part of the initial therapy. On the other hand, vancomycin should not be overused, because it is expensive, it is potentially toxic, and it can be associated with the emergence of resistant organisms. In addition, certain of the beta-lactam–resistant gram-positive organisms, such.
AB - To the Editor: The question of whether vancomycin should be included routinely in the initial empirical antibiotic regimen for febrile, neutropenic patients with cancer is important and relevant. Gram-positive organisms are increasing in incidence, and many are resistant to or poorly covered by most regimens that do not contain vancomycin. Thus, some authorities have recommended that vancomycin be part of the initial therapy. On the other hand, vancomycin should not be overused, because it is expensive, it is potentially toxic, and it can be associated with the emergence of resistant organisms. In addition, certain of the beta-lactam–resistant gram-positive organisms, such.
UR - http://www.scopus.com/inward/record.url?scp=0024544733&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024544733&partnerID=8YFLogxK
U2 - 10.1056/NEJM198904063201415
DO - 10.1056/NEJM198904063201415
M3 - Letter
C2 - 2927469
AN - SCOPUS:0024544733
SN - 0028-4793
VL - 320
SP - 939
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 14
ER -